DBV Technologies (NASDAQ:DBVT) Posts Earnings Results, Misses Estimates By $0.42 EPS

DBV Technologies (NASDAQ:DBVT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42), Zacks reports. The company had revenue of $0.90 million during the quarter, compared to analysts' expectations of $1.11 million. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%.

DBV Technologies Stock Down 5.4%

Shares of NASDAQ DBVT opened at $19.87 on Friday. The firm has a market cap of $1.11 billion, a PE ratio of -4.46 and a beta of -0.97. The business has a 50 day moving average price of $20.89 and a two-hundred day moving average price of $18.87. DBV Technologies has a fifty-two week low of $7.53 and a fifty-two week high of $26.18.

Institutional Trading of DBV Technologies

Institutional investors have recently bought and sold shares of the company. Truvestments Capital LLC increased its holdings in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company's stock worth $75,000 after purchasing an additional 1,620 shares during the period. Royal Bank of Canada bought a new stake in shares of DBV Technologies in the fourth quarter valued at about $34,000. Persistent Asset Partners Ltd acquired a new stake in DBV Technologies during the fourth quarter worth about $115,000. Cetera Investment Advisers acquired a new stake in DBV Technologies during the fourth quarter worth about $251,000. Finally, Two Sigma Investments LP bought a new position in DBV Technologies during the third quarter valued at about $167,000. Institutional investors and hedge funds own 71.74% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of DBV Technologies from a "sell" rating to a "hold" rating in a research report on Saturday. Citizens Jmp upped their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Friday. Finally, Guggenheim reiterated a "buy" rating and issued a $51.00 price target on shares of DBV Technologies in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $40.25.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.